Sign in
Taking people in United StatesPhase 1/2

Tests GI-102 alone and with other drugs in advanced solid tumors

Tests GI-102, alone or with other cancer drugs, in adults with advanced solid tumors.

Key facts

Who runs it
GI Innovation, Inc.
Where
Cleveland, Jacksonville, New York, Rochester, and Scottsdale, United StatesSee the 5 sitesAlso in 1 other country, 5 sites
Trial code
Registry title
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Status
Recruiting
Phase
Phase 1/2
People taking part
358 people, planned
Started
30 May 2023
Expected to end
24 Apr 2027
Type of study
Interventional, 7 groups
Treatments tested
  • GI-102 subcutaneous (SC)
  • GI-102
  • doxorubicin
  • paclitaxel
  • bevacizumab
  • eribulin
  • trastuzumab deruxtecan (T-DXd)
  • pembrolizumab
Record updated
25 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic solid tumors that can be measured, who are fairly active in daily life.

Age
18 years or older (19 or older where local rules say so)
Sex
Men and women
Disease stage
Advanced or metastatic solid tumor with measurable disease (RECIST v1.1); daily-life activity score ECOG 0-1
Earlier treatment
Side effects from earlier cancer treatment or surgery must have settled to Grade 1 or lower, except hair loss and Grade 2 nerve damage in hands or feet. People living with HIV can join if on anti-retroviral therapy with well-controlled HIV.

Main reasons for not taking part

  • Active brain metastases or cancer in the membranes around the brain
  • Another active cancer
  • Active or past Hepatitis B, or active Hepatitis C
  • Active autoimmune disease needing systemic treatment in the past 2 years
  • Cancer treatment within 4 weeks before the study, or radiotherapy within 2 weeks

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening
  • Has adequate organ and marrow function as defined in protocol
  • Measurable disease as per RECIST v1.1
  • ECOG performance status 0-1
  • Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy
  • HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol

Who cannot take part

  • Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration
  • Previous immunotherapies related to mode of action of GI-102
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1
  • Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment
  • Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
  • An active second malignancy
  • Has active or a known history of Hepatitis B or known active Hepatitis C virus infection
  • Has active tuberculosis or has a known history of active tuberculosis
  • History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis
  • Has an active autoimmune disease that has required systemic treatment in past 2 years
  • Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102; Other protocol defined inclusion exclusion criteria may apply
  • Has known active CNS metastases and/or carcinomatous meningitis

Where in United States

Also in 1 other country, 5 sites

  • Cleveland ClinicCleveland, United StatesContact: Wen Wee Ma, MBBSTaking people
  • Mayo Clinic in FloridaJacksonville, United StatesContact: Yujie Zhao, MD, PhDTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Viswatej Avutu, MDTaking people
  • Mayo Clinic in MinnesotaRochester, United StatesContact: Jian Li Campian, MD, PhDTaking people
  • Mayo Clinic in ArizonaScottsdale, United StatesContact: Mahesh Seetharam, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

The 7 groups in the trial

  • GI-102Treatment being tested

    Dose escalation: GI-102 intravenous (IV), multiple ascending doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization: GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)

  • GI-102 subcutaneous (SC)Treatment being tested

    Dose escalation: GI-102 subcutaneous (SC), multiple ascending doses Dose expansion: GI-102 subcutaneous (SC), sRP2D

  • GI-102 + doxorubicinTreatment being tested

    Treatment: doxorubicin and GI-102

  • GI-102 + paclitaxel + bevacizumabTreatment being tested

    Treatment: paclitaxel, bevacizumab, and GI-102

  • GI-102 + eribulinTreatment being tested

    Treatment: eribulin and GI-102

  • GI-102 + trastuzumab deruxtecan (T-DXd)Treatment being tested

    Treatment: trastuzumab deruxtecan (T-DXd) and GI-102

  • GI-102 + pembrolizumabTreatment being tested

    Treatment: pembrolizumab and GI-102

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
Plain-language title
Tests GI-102 alone and with other drugs in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 November 2024